J 2020

The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma

GURÍN, Dominik, Marek SLÁVIK, Markéta HERMANOVÁ, Iveta SELINGEROVÁ, Tomáš KAZDA et. al.

Basic information

Original name

The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma

Authors

GURÍN, Dominik (203 Czech Republic, guarantor, belonging to the institution), Marek SLÁVIK (703 Slovakia, belonging to the institution), Markéta HERMANOVÁ (203 Czech Republic, belonging to the institution), Iveta SELINGEROVÁ (203 Czech Republic), Tomáš KAZDA (203 Czech Republic, belonging to the institution), Michal HENDRYCH (203 Czech Republic, belonging to the institution), Tetiana SHATOKHINA (804 Ukraine, belonging to the institution) and Marcela VESELÁ (203 Czech Republic)

Edition

JOURNAL OF ORAL PATHOLOGY & MEDICINE, HOBOKEN, WILEY, 2020, 0904-2512

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30109 Pathology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.253

RIV identification code

RIV/00216224:14110/20:00116131

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1111/jop.13055

UT WoS

000544754600001

Keywords in English

CD8; HPV; oropharyngeal squamous cell carcinoma; PD-L1; tumor-infiltrating lymphocytes

Tags

14110112, 14110812, podil, rivok

Tags

International impact, Reviewed
Změněno: 29/10/2020 13:38, Mgr. Tereza Miškechová

Abstract

V originále

Background We examined PD-L1 expression on tumor cells (TCs) and immune cells (ICs) and density of CD3(+)and CD8(+)tumor-infiltrating lymphocytes (TILs) in patients with oropharyngeal squamous cell carcinoma (OPSCC) and investigated their significance on clinicopathological characteristics and clinical outcomes. Methods In a cohort of 65 patients treated by definitive intensity-modulated radiotherapy (IMRT) with curative intent, immunohistochemical analysis of PD-L1 expression on TCs and ICs, and TIL subtyping was performed on primary biopsy tumor tissues, followed by prognostic evaluation of these immune response-related parameters including classification into four tumor immune microenvironment (TIM) types. To evaluate HPV status, p16 immunohistochemistry was performed. Results Densities of CD3(+)and CD8(+)TILs and PD-L1 expressions on TCs and ICs were significantly higher in p16+/HPV-mediated OPSCC. Patients with high densities of stromal CD8(+)TILs displayed significantly better overall survival (OS) and progression-free survival (PFS). PD-L1 expression neither on tumor cells nor on immune cells affected survival outcomes. Distribution of TIM types based on the combination of PD-L1 expression on TCs and densities of CD8(+)TILs is significantly different in p16+ compared with p16- OPSCC. In type III TIM (TC-PD-L1+/low CD8(+)TIL density), significantly better OS was shown in p16+ group compared with p16- OPSCC. Conclusion The prognostic and predictive role of tumor immune microenvironment was confirmed for patients with OPSCC. Combining HPV status with the evaluation of densities of CD8(+)TILs and PD-L1 expression including TIM classification might be of high clinical interest and warrants further prospective evaluation.
Displayed: 7/11/2024 19:32